Breaking Through Defenses, Delivering Hope
Transforming Treatments with Cell Therapies
Engineered to Target, Designed to Impact Lives
Our core technology focuses on engineering induced pluripotent stem cells (iPSCs) and differentiating them into mesenchymal stromal cells (iMSCs). We take advantage of the intrinsic ability of MSCs to home to sites of tumor and deliver our payload of therapeutic cytokines. Our therapies provide a scalable, off-the-shelf treatment, without needing patient-specific cell harvesting.
iMSCs
iPSCs
iMSCs
engineering induced pluripotent stem cells
iPSCs
engineering induced pluripotent stem cells
Bringing Hope to Ovarian Cancer
We are aiming to advance our lead cell therapy treatment, ERNA-101, into the clinic for the treatment of ovarian cancer as the first indication. Ovarian cancer currently lacks highly effective, widely applicable targeted therapies. Even when patients are treated successfully, there is a high recurrence rate. ERNA-101 offers new hope for women fighting ovarian cancer.
Download Fact Sheet
ERNA-101 is designed to activate and enhance the immune system's response to recognize and attack cancer cells. Our best-in-class, synthetic iMSCs represent a new class of precision-guided therapeutics, taking advantage of the MSC’s natural tumor-homing abilities to migrate directly to tumor sites, allowing them to slip through the tumor’s defenses and infiltrate tumor tissue.
The iMSCs can then deliver potent cytokines directly to the tumor microenvironment, ultimately triggering a strong immune response against the cancer cells.
